Abstract
NMOSD is a rare but severe relapsing remitting demyelinating disease that affects both adults and children. Most patients have pathogenic antibodies that target the central nervous system AQP4 protein. This review provides an update on our current understanding of the disease pathophysiology and describes the clinical, paraclinical features and therapeutic management of the disease.
Original language | English |
---|---|
Article number | 183772 |
Journal | BBA -Biomembranes |
Volume | 1863 |
Issue number | 12 |
Early online date | 9 Sept 2021 |
DOIs | |
Publication status | Published - 1 Dec 2021 |
Bibliographical note
© 2021, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/Funding: SKW was funded by a Wellcome Trust Clinical Research Career Development Fellowship (216613/Z/19/Z) during this work.
Keywords
- AQP4
- Immunotherapy
- MOGAD
- NMOSD
- Neuroinflammation
- Neuronal antibodies